Histological features such as tumour budding, perineural invasion, apical lymph node positivity, lymph node yield, lymph node ratio and molecular features such as microsatellite instability (MSI), KRAS, BRAF and CDX2 have been identified in their ability to guide prognostication and optimise adjuvant treatment. This evidence concerns the gene KRAS and neoplasm.